



4854 32001/905

• 10722 14-311-  
172009

HO

$C_b = pH[H^+] [OH^-]$

Analysis: Complete.  
Position: #120498 05  
Offset: &4005 980 011B  
Current status: Online.

Awaiting data input...

# INTRODUCTION TO PHARMACOKINETICS FOR THE NON- SPECIALIST

LIVE Online Academy

7.403.98E-08	2.51E-07	0.201
7.602.51E-08	3.98E-07	0.265
8.001.00E-08	1.00E-06	0.500
8.403.98E-09	2.51E-06	0.715
8.801.58E-09	6.31E-06	0.863
9.001.00E-09	1.00E-05	0.909
9.403.98E-10	2.51E-05	0.962
9.801.58E-10	6.31E-05	0.984
10.001.00E-10	1.00E-04	0.990

## COURSE OVERVIEW

Pharmacokinetics (PK) and pharmacodynamics (PD) play a key role in drug development, and a good understanding of the implications of PK/PD data is crucial when designing clinical trials or preparing a drug submission dossier. As a professional working with PK/PD data on a regular basis you must have a solid understanding of the topic to communicate effectively with the development teams - a daunting and challenging task, due to the breadth and complexity of the topic area.

This course assumes no prior PK knowledge, and aims to give you a broad understanding of this fascinating subject, using multiple case studies and relevant examples. You will learn what pharmacokinetics involves, what data is collected and its impact on the drug development process. By learning these skills you will be able to understand, communicate and challenge the data presented to you.

Grow your knowledge and confidence in PK/PD to fully understand the data and decisions made

$C_b = pH[H^+]$        $[OH^-]$

Analysis: Complete.  
Position: #120498 05  
Offset: &4005 980 011B  
Current status: Online.

Awaiting data input...

9.801.58E-10      6.31E-05      0.984

10.001.00E-10      1.00E-04      0.990

# Dr. Stefano Persiani

Dr. Stefano Persiani is currently Director of Translational Sciences and Pharmacokinetics at Rottapharm Biotech, Italy. After years working in academia, Dr. Persiani moved to the pharmaceutical industry and CRO sector holding different positions in R&D at Farmitalia Carlo Erba, Pharmacia, Upjon, and Zambon Group.

His experience within pharmaceutical companies and CROs ranges from drug discovery and lead optimization to early preclinical and full clinical development in different therapeutic areas including oncology, respiratory, CNS, anti-infective, cardiovascular, gastrointestinal, and rheumatology.

MEET  
THE  
TRAINER

# MODULE ONE

## **The Role of PK in Drug Development**

- What is PK? Understand the PK/PD model of therapeutics
- The importance of PK throughout the phases of drug development
- The increasing importance of PK in the go/no go decision
- Interdisciplinary interaction in the pharmaceutical industry – let's all speak the same language
- PK as a tool in strategic decision making
- How PK knowledge is used to reduce time and cost
- What do we measure and how do we measure it?

# MODULE TWO

## Fundamentals of Pharmacokinetics 1

- Absorption
- Distribution
- Metabolism
- Excretion
- Elimination
- Disposition
- PK in drug candidate selection

# MODULE TWO

## **Fundamentals of Pharmacokinetics 2**

- Essential drug concentrations such as in blood, plasma and excretions
- Basic terminology such as half-life, clearance and volume of distribution
- Essential measurements: end points such as  $C_{max}$ ,  $T_{max}$ , and AUC
- Other essentials, drug metabolism, drug transporters and the blood/brain barrier
- Key features and misconceptions

# MODULE THREE

## **Pharmacokinetic Analysis**

- Examine different types of PK/PD analysis
- Compartmental vs non-compartmental analysis: Jargon explained

## **Drug-Drug Interactions**

- Cytochrome P450 - What are they? What do they do? What do they tell us?
- In-vitro and in-vivo measurements
- Species differences- extrapolation to man
- Dangers and pitfalls

## **Pre-clinical Pharmacokinetics**

- Studies with radiolabelled drugs
- Toxicokinetics

# MODULE FOUR

## **Pharmacokinetic and Pharmacodynamic Studies**

- Different routes of administration
- Single dose vs multi dose PK
- Bioavailability and bioequivalence
- Effects of food, gender, race, age, medical conditions
- Use of biomarkers in PD analysis
- Human radiolabelled studies



# MODULE FIVE

## **Pharmacokinetics and Regulatory Guidelines**

- What do the Regulators say?
- The impact of the EU Directive
- EMA guidelines: Paediatric, hepatically impaired, renally impaired
- Differences between FDA and EMA requirements

## **Reporting of Pharmacokinetic Data**

- How do we report data?
- What are we trying to demonstrate?
- Common pitfalls



# WHO IS THIS COURSE FOR?

This course is aimed at anyone who comes into contact with PK/PD data but does not require specialist knowledge in the field. No previous knowledge of PK/ PD is assumed.

The course is designed to give an overview of the field without the equations. It will be of particular benefit to professionals working in:

- Development
- Preclinical
- Phase I
- Licensing
- Clinical Operations
- Regulatory Affairs
- Data Management
- Drug Safety
- Clinical Pharmacology
- Registration



Brought to you by  
**informaconnect**

## For information contact our training consultants

Jessica Purnell

Jessica.Purnell@informa.com

+44 (0)20 7551 9521

Group bookings

Receive 10% off for 3-4 bookings

Receive 15% off for 5+ bookings

Cb =pH[H<sup>+</sup>] [OH<sup>-</sup>]

Analysis: Complete.  
Position: #120498 0  
Offset: &4005 980  
Current status: Online.

Awaiting data input...